Syndeio Biosciences
Syndeio Biosciences raises $90M Series at $450M valuation
Syndeio Biosciences: Series Funding Round
Syndeio Biosciences has successfully raised $90M in Series funding, reaching a valuation of $450M.
Company Overview
Developer of precision neurotherapeutics for CNS diseases
Funding Details
The Series round was led by Eli Lilly and Company, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Indianapolis, IN
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
Syndeio Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Eli Lilly and Company: Verified investor in Series
- ARCH Venture Partners: Verified investor in Series
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free